In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.
In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID.
In COVID-19 clinical update #95, Daniel Griffin discusses new CDC guidelines for isolation and quarantine, EUA for Molnupiravir, children and COVID, vaccine safety in 5-11 year olds, Omicron outbreaks in Nebraska and Denmark, Baylor’s COVID vaccine, and COVID-OUT for ivermectin.
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
In COVID-19 clinical update #93, Dr. Griffin summarizes Omicron fitness, S-gene target failure, monoclonal efficacy against Omicron, vaccination, monoclonals, and disease in children, persistence of memory B cells in the elderly, infection and vaccine induced immunity, protection against severe illness and death by a third mRNA vaccine dose, high flow oxygen versus intubation, and therapeutic anticoagulation.
TWiV reviews the impact of vaccination on SARS-CoV-2, the latest information on Omicron, West Nile virus transmission by organ transplantation, and why a 16 week interval between doses of BNT162b2 vaccine is better than a shorter interval.
The New York City Virus Hunters join TWiV to reveal how local students engage in safe virus surveillance and conduct science research right in their neighborhoods, followed by an update on variant of concern Omicron.
TWiV reveals all that we know so far about the variant of concern B.1.1.529, also called Omicron, and describes a study on the ability of the alpha, beta, and delta variants to reproduce in cells in culture and induce membrane fusion.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.